Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia

86Citations
Citations of this article
104Readers
Mendeley users who have this article in their library.

Abstract

Disorders of uric acid metabolism may be associated with pathological processes in many diseases, including diabetes mellitus, cardiovascular disease, and kidney disease. These diseases can further promote uric acid accumulation in the body, leading to a vicious cycle. Preliminary studies have proven many mechanisms such as oxidative stress, lipid metabolism disorders, and rennin angiotensin axis involving in the progression of hyperuricaemia-related diseases. However, there is still lack of effective clinical treatment for hyperuricaemia. According to previous research results, NPT1, NPT4, OAT1, OAT2, OAT3, OAT4, URAT1, GLUT9, ABCG2, PDZK1, these urate transports are closely related to serum uric acid level. Targeting at urate transporters and urate-lowering drugs can enhance our understanding of hyperuricaemia and hyperuricaemia-related diseases. This review may put forward essential references or cross references to be contributed to further elucidate traditional and novel urate-lowering drugs benefits as well as provides theoretical support for the scientific research on hyperuricemia and related diseases.

Cite

CITATION STYLE

APA

Sun, H. L., Wu, Y. W., Bian, H. G., Yang, H., Wang, H., Meng, X. M., & Jin, J. (2021, July 14). Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia. Frontiers in Pharmacology. Frontiers Media S.A. https://doi.org/10.3389/fphar.2021.667753

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free